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A biomimic reconstituted high-density-lipoprotein-based drug and p53 gene co-delivery system (rHDL/CD-PEI/p53
complexes) was fabricated as a targeted co-delivery nanovector of drug and gene for potential bladder cancer
therapy. Here, CD-PEI was utilized to effectively condense the p53 plasmid, to incorporate the plasmid into rHDL,
and to act as an antitumor drug to suppress tumor angiogenesis. The rHDL/CD-PEI/p53 complexes exhibited
desirable and homogenous particle size, neutral surface charge, and low cytotoxicity in vitro. The results of confocal
laser scanning microscopy and flow cytometry confirmed that SR-BI-targeted function induced specific cytoplasmic
delivery and high gene transfection efficiency in MBT-2 murine bladder cells. In addition, rHDL/CD-PEI/p53 complexes
co-delivering CD and p53 gene achieved synergistic angiogenesis suppression by more effectively downregulating the
expression of vascular endothelial growth factor (VEGF) messenger RNA (mRNA) and protein via different pathways
in vitro. In vivo investigation on C3H/He mice bearing MBT-2 tumor xenografts revealed that rHDL/CD-PEI/p53
complexes possessed strong antitumor activity. These findings suggested that rHDL/CD-PEI/p53 complexes could
be an ideal tumor-targeting system for simultaneous transfer of drug and gene, which might be a new promising
strategy for effective bladder cancer therapy.
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Bladder cancer is one of the most common cancers.
There were approximately 70,980 cases diagnosed with
bladder cancer in the USA in 2009, of which 14,330 pa-
tients would likely succumb to the disease [1]. Gene
therapy has garnered significant attention as a thera-
peutic approach for bladder cancer. From a clinical point
of view, this disease is an ideal target for gene therapy
[2]. Efficient delivery of genetic material to the required
cells within a patient without significant toxicity and side
effect in gene therapy requires an ideal delivery vector,
which has been extensively studied for several decades
[3]. Reconstituted high-density lipoprotein (rHDL) is the
synthetic form of the endogenous human HDL. Both* Correspondence: qiaohongouyang@163.com
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reproduction in any medium, provided you
link to the Creative Commons license, and irHDL and endogenous human HDL possess similar
physicochemical properties. In the past decades, rHDL
has been successfully developed as a scavenger receptor
class B type 1 (SR-BI)-targeting gene carrier [4], which
displayed promising application potential in vivo.
Antiangiogenic therapy has been well recognized as
an effective antitumor strategy [5]. Among various
angiogenesis-related growth factors, vascular endothelial
growth factor (VEGF) has been demonstrated to be a
major contributor to angiogenesis that occurs in many
solid tumors including breast, bladder, and prostate can-
cers [6]. It has been reported that p53 gene therapy could
inhibit tumor-associated angiogenesis by downregulating
VEGF expression [7]. On the other hand, angiotensin II
type 1 receptor (AT1R), a widely overexpressed receptor
in various neoplastic cells, was recognized to play an im-
portant role in tumor angiogenesis and progression. Therele is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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candesartan (CD) exerted beneficial effects on tumor pro-
gression by competitively inhibiting the AT1R signaling
pathway and downregulating VEGF expression [8].
Co-delivery systems simultaneously transporting anti-
cancer drug and gene into the same cancer cells by multi-
functional nanovectors may provide a new paradigm in
cancer treatment. In this study, an rHDL-based system
was developed for effective p53 gene delivery and com-
bined antiangiogenesis therapy in a bladder cancer model.
CD-PEI was first synthesized and then employed to con-
struct a lipophilic core of rHDL (Lipos/CD-PEI). The cat-
ionic CD-PEI was served to condense the p53 plasmid to
formulate Lipos/CD-PEI/p53 complexes. Finally, func-
tional protein apoA-I was introduced to eventually assem-
ble the delivery system (rHDL/CD-PEI/p53 complexes).
Methods
Cell Culture and Animal Model
The MBT-2 murine bladder cell line was cultured in
DMEM (Gibco, USA) supplemented with 10 % FBS
(HyClone, USA), 100 U/ml penicillin, and 100 μg/ml
streptomycin in a humidified atmosphere of a 95 % air/5 %
CO2 incubator at 37 °C. Male C3H/He mice (7 weeks old)
were maintained at standard conditions with free access to
food and water. All animal experiments were conducted in
strict accordance with the National Institute of Health
Guide for the Care and Use of Laboratory Animals. The
MBT-2-tumor-bearing mice models were established by
subcutaneous inoculation of the MBT-2 cell suspension to
the flank of mice.
Synthesis of CD-PEI
CD-PEI was prepared according to a previous report [9]
and characterized by 1H NMR.
Preparation of rHDL/CD-PEI/p53 Complexes
Preparation of Lipos/CD-PEI
A thin-film dispersion method was employed to con-
struct Lipos/CD-PEI as previously reported [10] with
some modifications. Briefly, 60 mg of PC, 6 mg of chol-
esterol, and 12 mg of CE were dissolved in 2 ml of or-
ganic solvent (chloroform:methanol = 1:1, v/v), and the
solvent of lipid solutions was evaporated with a rotary
evaporator at 30 °C until a thin film was formed. The
trace solvent residue was finally removed with a stream
of nitrogen gas. Five hundred microliters of CD-PEI so-
lution (10 mg/ml), 50 μl of sodium cholate solution (30
mg/ml in phosphate-buffered saline (PBS) buffer), and
Tris buffer (0.1 M KCl, 10 mM Tris, 1 mM EDTA, pH
8.0) were added to dissolve the thin film. The mixture
was vortexed thoroughly for 5 min, followed by ultrasoni-
cation using an ultrahomogenizer (JY92II, Ningbo, China)
until a clear suspension was obtained. The dispersion wasthen filtered through a 0.22-μm filter and dialyzed to re-
move the free sodium cholate (MWCO 7500 Da, 2 L × 3).
Finally, the prepared Lipos/CD-PEI complexes were col-
lected and stored at 4 °C until further use.Preparation of Lipos/CD-PEI/p53 Complexes
The p53 plasmid was dissolved in PBS buffer to obtain a
final concentration of 0.1 mg/ml and then added drop-
wise into the above-prepared Lipos/CD-PEI complexes
with vortex to formulate Lipos/CD-PEI/p53 complexes.Preparation of rHDL/CD-PEI/p53 Complexes
Lipos/CD-PEI/p53 complexes were incubated with 100 μl
of apoA-I solution (30 mg/ml in PBS buffer) to form
rHDL/CD-PEI/p53 complexes under 600-rpm stirring at
25 °C for 8 h. The prepared rHDL/CD-PEI/p53 complexes
were obtained and stored at 4 °C until further use.Particle Size, Zeta Potential, and Morphology Observation
The particle size and zeta potential of Lipos/CD-PEI/p53
and rHDL/CD-PEI/p53 complexes were measured by a
Malvern Zetasizer. The morphological observation was
performed by transmission electron microscopy.Cytotoxicity, Cellular Distribution, and Transfection
Studies
The MBT-2 cells were seeded in plates at a density of 1 ×
105 cells/ml and incubated until 70–80 % cell confluence
before being subjected to experiments.
The cytotoxicity of the complexes was measured by
MTT assay. PEI 1.8K/pDNA (w/w = 10, pDNA indicates
the non-functional plasmid), Lipos/CD-PEI/pDNA, and
rHDL/CD-PEI/pDNA complexes containing various con-
centrations of PEI were co-cultured with cells for 24 h.
The pDNA was labeled with the fluorescent dye YOYO-
1 and employed to construct complexes as mentioned in
“Preparation of rHDL/CD-PEI/p53 Complexes.” After in-
cubation with the complexes at 37 °C for 2 h, cells were
treated with 50 nM LysoTracker Red for 30 min and
rinsed three times with PBS before staining with Hoechst
33342 (10 μg/ml). The cellular distribution of complexes
was observed by confocal laser scanning microscopy.
Transfection of PEI 25K/pEGFP-C3 (N/P = 10), Lipos/
CD-PEI/pEGFP-C3, and rHDL/CD-PEI/pEGFP-C3-com-
plex-mediated reporter gene pEGFP-C3 in MBT-2 cells
was qualitatively and quantitatively investigated as de-
scribed previously [11]. The expression of green fluores-
cent protein (GFP) in cells was observed under an
inverted fluorescence microscope, and the transfection ef-
ficiency of complexes was quantified by GFP fluorescence
intensity and GFP-positive cells using flow cytometry.
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PCR, western blotting, and ELISA assays were con-
ducted according to a previous report [12].
In Vivo Antitumor Assay
In vivo antitumor efficacy of rHDL/CD-PEI/p53 com-
plexes was evaluated on MBT-2 tumor xenograft models.
All MBT-2-tumor-bearing nude mice were weighed and
randomly divided into four groups (n = 6). All the formu-
lations were administrated via tail vein at a dose of 30 μg
CD and/or 50 μg p53 gene/mouse. The measurement of
tumor volumes and the injection of formulations were re-
peated every 2 days for 2 weeks. At the end of treatment,
all mice were sacrificed and their tumor tissues were har-
vested. The tumor tissues were pictured and then sub-
jected to hematoxylin and eosin (H&E) staining.
Results and Discussion
Characterization of CD-PEI
The conjugation of CD with PEI was conducted via ami-
dation reaction. The cationic amido groups of PEI were
employed to condense the plasmid, and the highly
hydrophobic CD was introduced to incorporate the PEI/
pDNA complexes with the hydrophobic core of rHDL
through hydrophobic interaction. Here, the CD-PEI
served not only to package the plasmid but also to act as
a linker to integrate the plasmid with rHDL. The chemical
structure of CD-PEI was confirmed by 1H NMR in D2O.
Compared with the spectrum of PEI, the proton peaks of
–NHCH2CH2– from CD-PEI appeared at 2.2–3.3 ppm,
whereas PEI only appeared at about 2.7 ppm. Moreover,
the peaks at δ 1.2–1.5 ppm (t, –CH3) and δ 6.3–7.1 ppm
(m, Ar-H) were assigned to CD. These results provided
decisive evidences that CD was successfully grafted to the
PEI chain.
Particle Size, Zeta Potential, and Morphology Observation
The particle size and zeta potential are in great relation
to the performance of the delivery system, which should
be carefully tuned to achieve the optimal therapeutic ef-
fect in cancer therapy. Multiple researches have demon-
strated that the biodistribution behavior and cellular
uptake efficiency of complexes are relevant to their par-
ticle size and zeta potential [13, 14]. In general, a small
size usually leads to preferable cellular uptake and super-
ior therapeutic effect of particles, for they can be readily
recognized and transported by the corresponding recep-
tor or channel [12]. On the other hand, it is well estab-
lished that the positively charged particles tend to
interact with negatively charged proteins in the blood
and extracellular matrix, which might lead to preferable
uptake by the liver instead of targeting cells and could be
an obstacle for the effective transfection of plasmid [15].
Herein, the particle size and zeta potential of Lipos/CD-PEI/p53 and rHDL/CD-PEI/p53 complexes were analyzed.
As shown in Fig. 1b, both Lipos/CD-PEI/p53 and rHDL/
CD-PEI/p53 complexes showed a nanoscale size under
100 nm. Comparing the particle size of these two com-
plexes, a minor increase was observed in the rHDL/CD-
PEI/p53 complexes group, which indicated the successful
coating of apoA-I protein. This conclusion was also con-
firmed by the significant difference of zeta potential be-
tween them (Fig. 1c). Moreover, both Lipos/CD-PEI/p53
and rHDL/CD-PEI/p53 complexes displayed a spherical
shape and compacted structure with good dispersity, as
evidenced by the representative TEM image in Fig. 1d,
which further proves the formation of compact nanosized
particles.
Cytotoxicity, Cellular Distribution, and Transfection Study
PEI is one of the most effective non-viral gene vectors
owing to its condensed positive charges. However, the
positive charges may interact with a negatively charged
cell membrane and cause severe cytotoxicity both
in vitro and in vivo [11]. The cytotoxicity of PEI 1.8K/
pDNA (w/w = 10), Lipos/CD-PEI/pDNA, and rHDL/
CD-PEI/pDNA complexes was evaluated against MBT-2
cells by MTT assay. Cells were treated with complexes
containing various PEI concentrations ranging from 2 to
100 μg/ml. As presented in Fig. 2a, significant inhibitory
effects of PEI 1.8K/pDNA and Lipos/CD-PEI/pDNA
complexes were observed. PEI 1.8K/pDNA and Lipos/
CD-PEI/pDNA complexes displayed 47.26 and 40.87 %
mortality on MBT-2 cells at 100 μg/ml, respectively,
which might be related to their considerable positive
charges. In contrast, compared with PEI 1.8K/pDNA
and Lipos/CD-PEI/pDNA complexes in all concentra-
tions, the cell viability of rHDL/CD-PEI/pDNA complexes
was higher. Especially at the PEI concentration of 100 μg/
ml, the serious cytotoxicity of Lipos/CD-PEI/pDNA com-
plexes was dramatically decreased after apoA-I protein
shielding, indicating that rHDL as a biomimic delivery
vector could lower the cytotoxicity of PEI. Moreover, the
pDNA concentrations adopted in the following studies
were all lower than 100 μg/ml; as a result, rHDL/CD-PEI/
pDNA complexes could be identified as a safe delivery
system for both in vitro and in vivo application.
It has been reported that rHDL could specifically deliver
its encapsulated payload into the cytoplasm via the non-
endocytic pathway [16]. By employing confocal laser
scanning microscopy to localize the endosome and encap-
sulated plasmid, we hope to explore the cellular distribu-
tion of rHDL/CD-PEI/pDNA complexes and, in turn,
explain their transfection mechanism. As depicted in
Fig. 2b, the red fluorescence dots represented endosomes
labeled with LysoTracker Red and the nuclei were stained
with Hoechst 33342 (blue color). The intracellular green
fluorescence dots induced from YOYO-1-labeled pDNA
Fig. 1 a 1H NMR of PEI and CD-PEI, b particle size, c zeta potential, and d TEM of Lipos/CD-PEI/p53 and rHDL/CD-PEI/p53 complexes. Scale bars 100 nm
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payload of different complexes. After 2 h of incubation,
significant differences were observed between the cellular
distribution of Lipos/CD-PEI/pDNA and rHDL/CD-PEI/
pDNA complexes. Most the green dots in the Lipos/CD-
PEI/pDNA group merged with a red color (yellow), sug-
gesting the payload of Lipos/CD-PEI/pDNA complexes
was undergoing the endocytosis process. In contrast, none
of the payloads in the rHDL/CD-PEI/pDNA group
yielded a yellow color, indicating they all existed in the
cytoplasm. We speculated that upon recognition of
apoA-I by SR-BI, the cell membrane would undergo
membrane reorganization, resulting in the formation of a
non-aqueous “channel” and subsequent cross-membrane
transfer of CD-PEI/pDNA cargo from rHDL to cytosolic
compartments without internalization of the intact rHDL/
CD-PEI/pDNA complexes. Bypassing the endocytosis
process will guarantee the integrity of the CD-PEI/pDNA,
which is beneficial to the transfection of the plasmid.
In order to determine the influence of non-endocytotic
delivery effect on the transfection efficiency of rHDL/CD-
PEI/pEGFP-C3 complexes, the in vitro transfection and
expression of GFP were qualitatively and quantitatively
analyzed by inverted fluorescence microscopy and flow cy-
tometry, respectively. PEI 25K/pEGFP-C3 complexes with
the N/P ratio of 10 were employed as a positive control.
As displayed in Fig. 2c, compared with Lipos/CD-PEI/
pEGFP-C3 complexes, the fluorescence image of rHDL/
CD-PEI/pEGFP-C3 complexes showed a significant in-
crease in transfection efficiency, which was even stronger
than that in PEI 25K/pEGFP-C3 complexes. A similarconclusion could also be reached from the quantitative
analysis using flow cytometry. The GFP-positive cells in
rHDL/CD-PEI/pEGFP-C3 complexes were 3.24-fold
higher than those in Lipos/CD-PEI/pEGFP-C3 complexes
and were even 1.26-fold higher than those in PEI 25K/
pEGFP-C3 complexes. The discrepancy of transfection
capacity between Lipos/CD-PEI/pEGFP-C3 and rHDL/
CD-PEI/pEGFP-C3 complexes demonstrated that the SR-
BI-receptor-mediated non-endocytotic delivery of CD-
PEI/pEGFP-C3 contributed to the evaluated transfection
efficiency of rHDL/CD-PEI/pEGFP-C3 complexes.
Synergistic Therapeutic Effect of CD and p53
VEGF is a potent and specific mitogen for endothelial
cells, which has been considered as the most important
cytokine in angiogenesis and has proved to be a suitable
target for cancer therapy. Hence, the expression of VEGF
messenger RNA (mRNA) and protein in MBT-2 cells
transfected with rHDL/CD-PEI/p53 complexes was evalu-
ated by quantitative reverse transcription PCR (qRT-PCR),
western blotting, and ELISA assays, respectively.
High Ang II concentration was employed to upregulate
VEGF and AT1R expression [17]. As shown in Fig. 3a,
treatment with Lipos/CD-PEI/p53 or rHDL/CD-PEI/
pDNA complexes for 24 and 48 h respectively resulted in
the lowered level of VEGF mRNA in MBT-2 cells. More
importantly, rHDL/CD-PEI/p53 complexes which simul-
taneously delivered CD and p53 gene into the same cells
further potentiated such suppression effect in VEGF
mRNA level. It was noted that the VEGF mRNA level in
cells treated with rHDL/CD-PEI/p53 complexes was 2.91-
Fig. 2 a Cell viabilities of MBT-2 cells incubated with different complexes at various PEI concentrations. b Intracellular trafficking of the YOYO-1-labeled
rHDL/CD-PEI/pDNA complexes in MBT-2 cells by CLSM. c In vitro GFP expression mediated by PEI 25K/pEGFP-C3 (N/P = 10), Lipos/CD-PEI/pEGFP-C3,
and rHDL/CD-PEI/pEGFP-C3 complexes in MBT-2 cells. Results are expressed as mean ± SD (n = 5). *P < 0.05 and **P < 0.01. Scale bars 20 μm
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than the basal level of VEGF mRNA in untreated cells
after 48 h of treatment, regardless that both Ang II and
endogenous mutant p53 upregulated VEGF expression
[18, 19]. The synergy effect of the two therapeutic agents(CD and p53 gene) was further supported by the reduced
VEGF protein expression observed by western blotting
assay (Fig. 3c). On the other hand, ELISA (Fig. 3d) analysis
showed that, at 48 h post-transfection, rHDL/CD-PEI/p53
complexes as a co-delivery system more dramatically
Fig. 3 Synergistic therapeutic effect of rHDL/CD-PEI/p53 complexes in suppressing VEGF and AT1R expression in MBT-2 cells. Ang II (100 nM) was
utilized to simulate an in vivo tumor microenvironment with high Ang II concentration. PCR assay of the suppression on VEGF (a) and AT1R (b)
mRNA levels. c Western blotting assay. d ELISA assay. Results are expressed as mean ± SD (n = 5). *P < 0.05 and **P < 0.01
Fig. 4 The tumor volume curve (a), typical images of ex vivo tumor tissues (b), and H&E staining (×200) of tumor tissues (c) of MBT-2-tumor-bearing
C3H/He mice after intravenous administration of saline and different complexes, respectively. The measurement of tumor volumes and the injection of
formulations were repeated every 2 days for 2 weeks. Results are represented as mean ± SD (n = 6). **P < 0.01
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Ang II and endogenous mutant p53 compared with an
untargeting delivery system (Lipos/CD-PEI/p53) or a
mono-delivery system (rHDL/CD-PEI/pDNA complexes),
which was consistent with the abovementioned qRT-PCR
and western blotting assays. All these results strongly
demonstrated that effective co-delivery of CD and p53
gene into MBT-2 cells using rHDL/CD-PEI/p53 com-
plexes achieved synergistic effect in suppressing overex-
pression of the angiogenesis-related gene VEGF, which
might ultimately restrain tumor-associated angiogenesis.
Furthermore, Ang II reportedly upregulated VEGF ex-
pression through AT1R and inhibition of AT1R downreg-
ulated the Ang-II-dependent VEGF expression [20]. To
confirm whether CD, an ARB, inhibited VEGF expres-
sion by downregulating AT1R expression, qRT-PCR and
western blotting analysis were conducted to assess the
expression level of AT1R mRNA and protein. Figure 3b,
c shows that Lipos/CD-PEI/p53 complexes exhibited the
highest expression of AT1R mRNA and protein, which
might be related to their poor tumor-targeting ability.
However, it was worth mentioning that rHDL/CD-PEI/
pDNA complexes achieved almost the same level of
AT1R mRNA and protein expression to rHDL/CD-PEI/
p53 complexes, regardless of the incorporated plasmid.
Taking the results from VEGF and AT1R expression ana-
lysis into consideration, it was evidenced that it was CD
(not p53 gene) that specifically reversed Ang-II-inducible
VEGF overexpression by downregulating AT1R expression.
Taken together, these results demonstrated that down-
regulation of VEGF expression was punctuated via dif-
ferent pathways (Ang II-AT1R and p53-dependent
pathways) by which CD and p53 gene act synergistically.
In Vivo Antitumor Efficacy and Tumor Angiogenesis
Suppression
The potential in vivo synergistic antitumor efficacy of
the rHDL/CD-PEI/p53 co-delivery system was further
assessed in MBT-2-xenografted C3H/He mice. As shown
in Fig. 4a, although tumor growth was suppressed to
some extent after administration of the untargeting de-
livery system (Lipos/CD-PEI/p53) or the mono-delivery
system (rHDL/CD-PEI/pDNA complexes), the combined
therapy of CD and p53 gene appeared to be much more
potent when the animals were treated with rHDL/CD-
PEI/p53 complexes, for the final tumor volumes in the
rHDL/CD-PEI/p53 group were merely 385.07 ± 86.19
mm3. This conclusion was also confirmed by the typical
images of ex vivo tumor tissues (Fig. 4b).
The therapeutic efficiency was also detected by H&E
staining of tumor tissues. The results were in accord
with the tumor growth inhibition. As displayed in Fig. 4c,
almost all tumor cells were seen arranging in nests and
exhibiting typical tumor cell morphology in the salinegroup. In contrast, various degrees of coagulative necro-
sis were observed in different treatment groups. There
was a clear boundary between the necrotic region and
non-necrotic region. In the necrotic region, tumor cells
were more heterogenous with high cellular polymorph-
ism; severe damage was seen with nuclear pyknosis, cell
necrosis, and cell lysis; and to some extent, cell frag-
ments were also observed. Among all the treatment
groups, the rHDL/CD-PEI/p53 group presented the
most serious coagulative necrosis with the largest area of
eosinophilic staining.
All the above results could be due to the synergetic
anticancer mechanism of CD and p53 gene. Overall, the
rHDL/CD-PEI/p53 complexes we constructed had great
potential as co-delivery systems for efficient cancer ther-
apy via synergistic mechanism.Conclusions
In this study, a biomimic reconstituted high-density-
lipoprotein-based drug and p53 gene co-delivery system
(rHDL/CD-PEI/p53 complexes) based on SR-BI targeting
delivery and combined tumor therapy strategy was suc-
cessfully constructed for simultaneously tumor-targeted
delivery of CD and p53 gene. Combined CD and p53 gene
therapy using a biomimic rHDL-based co-delivery system
might be an effective strategy for improved antiangiogenic
treatment in cancer, which deserves further investigations
towards the thorough mechanism of action in vivo and
potential clinical application.
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